|
97 Companies |
|
25 Products |
|
25 Products |
|
20 Mechanisms of Action |
|
184 Trials |
|
8296 News |
|
| «12...134135136137138139140141142143144145146» |
- || Enrollment change: DAP Registry: Duke Autoimmunity in Pregnancy Registry (clinicaltrials.gov) - Dec 9, 2014
P=N/A, N=500, Recruiting, Sponsor: Duke University
N=200 --> 500
- Eysuvis (loteprednol etabonate nano-suspension 0.25%) / Kala Pharma
Enrollment closed, Trial primary completion date: Kauai: Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (clinicaltrials.gov) - Nov 25, 2014
P2, N=150, Active, not recruiting, Sponsor: Kala Pharmaceuticals, Inc.
N=200 --> 500 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Jan 2015
- | iscalimab (CFZ533) / Novartis
New P2 trial: Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome (clinicaltrials.gov) - Nov 14, 2014
P2, N=30, Recruiting, Sponsor: Novartis Pharmaceuticals
- Enrollment change: Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=40, Recruiting, Sponsor: University of Rochester
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Jan 2015 N=30 --> 40
- New P3 trial: Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye (clinicaltrials.gov) - Oct 10, 2014
P3, N=30, Not yet recruiting, Sponsor: Universidad Nacional de Colombia
- Enrollment open: TOYOTA: Effect of Debridement-scaling on the Relief of Dry Eye Signs and Symptoms in Sjogren's Syndrome (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=14, Recruiting, Sponsor: University of Waterloo
N=30 --> 40 Not yet recruiting --> Recruiting
- || Cequa (nanomicellar cyclosporine) / Sun Pharma
New P2/3 trial, P2/3 data: Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca (clinicaltrials.gov) - Oct 2, 2014
P2/3, N=420, Recruiting, Sponsor: Ocular Technologies SARL
- |||| Enrollment open: Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sj (clinicaltrials.gov) - Sep 28, 2014
P2, N=60, Recruiting, Sponsor: Chang Gung Memorial Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- Trial primary completion date: Hematopoietic Stem Cell Support in Vasculitis (clinicaltrials.gov) - Sep 28, 2014
P1, N=10, Recruiting, Sponsor: Northwestern University
Active, not recruiting --> Recruiting Trial primary completion date: Aug 2015 --> Aug 2016
- |||| loteprednol etabonate / Generic mfg., cyclosporine ophthalmic emulsion / Generic mfg.
Trial completion, Trial primary completion date: Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease) (clinicaltrials.gov) - Aug 22, 2014
P2, N=102, Completed, Sponsor: Bausch & Lomb Incorporated
Trial primary completion date: Aug 2015 --> Aug 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Mar 2014
- |||||| Orencia (abatacept) / BMS
Enrollment open: ASAPIII: Efficacy and Safety of Abatacept in Patients With Primary Sj (clinicaltrials.gov) - Aug 22, 2014
P3, N=88, Recruiting, Sponsor: University Medical Centre Groningen
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Mar 2014 Not yet recruiting --> Recruiting
- baminercept (BG 9924) / Biogen
Enrollment closed, Trial primary completion date: Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sj (clinicaltrials.gov) - Aug 8, 2014
P2, N=72, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Dec 2014
- ianalumab (VAY736) / MorphoSys, Novartis
Trial primary completion date: PD of VAY736 in Patients With Primary Sjögren's Syndrome (clinicaltrials.gov) - Jul 27, 2014
P2, N=30, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Dec 2014 Trial primary completion date: Dec 2016 --> Jun 2017
- |||| Trial completion: A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES) (clinicaltrials.gov) - Jul 23, 2014
P2, N=90, Completed, Sponsor: Mitotech, SA
Trial primary completion date: Dec 2016 --> Jun 2017 Active, not recruiting --> Completed
- Trial initiation date: Evaluation of Therapeutic Effect of Bandage Contact Lenses ( BCL) on Dry Eye Caused by Sjogren's Syndrome (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=64, Completed, Sponsor: Jinyang Li
Active, not recruiting --> Completed Initiation date: Sep 2013 --> Mar 2013
- |||| R 348 / Rigel
Enrollment open: Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) (clinicaltrials.gov) - Jul 15, 2014
P2, N=60, Recruiting, Sponsor: Rigel Pharmaceuticals
Initiation date: Sep 2013 --> Mar 2013 Not yet recruiting --> Recruiting
- |||| R 348 / Rigel
Trial completion: To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca (clinicaltrials.gov) - Jul 15, 2014
P2, N=206, Completed, Sponsor: Rigel Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Trial completion: An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness (clinicaltrials.gov) - Jul 15, 2014
P1/2, N=24, Completed, Sponsor: Parion Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Eysuvis (loteprednol etabonate nano-suspension 0.25%) / Kala Pharma
New P2 trial: Kauai: Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (clinicaltrials.gov) - Jul 12, 2014
P2, N=150, Recruiting, Sponsor: Kala Pharmaceuticals, Inc.
- bupivacaine buccal / Oracain
Trial primary completion date: Clinical Trials With a Local Anesthetic Lozenge for the Treatment of Chronic Oral Pain (clinicaltrials.gov) - Jul 10, 2014
P2, N=31, Terminated, Sponsor: Hvidovre University Hospital
Active, not recruiting --> Completed Trial primary completion date: Jul 2013 --> Jan 2014
- bupivacaine buccal / Oracain
Trial termination: Clinical Trials With a Local Anesthetic Lozenge for the Treatment of Chronic Oral Pain (clinicaltrials.gov) - Jul 10, 2014
P2, N=31, Terminated, Sponsor: Hvidovre University Hospital
Trial primary completion date: Jul 2013 --> Jan 2014 Recruiting --> Terminated; Because of a very slow patient recruitment.
- bupivacaine buccal / Oracain
Enrollment change, Trial termination, Trial primary completion date: Clinical Trials With a Local Anesthetic Lozenge for the Treatment of Chronic Oral Pain (clinicaltrials.gov) - Jul 10, 2014
P2, N=31, Terminated, Sponsor: Hvidovre University Hospital
Recruiting --> Terminated; Because of a very slow patient recruitment. N=60 --> 31 | Recruiting --> Terminated | Trial primary completion date: Jul 2013 --> Jan 2014; Because of a very slow patient recruitment.
- Xolair (omalizumab) / Roche, Novartis
Trial primary completion date: Omalizumab for Lupus (clinicaltrials.gov) - Jul 3, 2014
P1, N=30, Recruiting, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
N=60 --> 31 | Recruiting --> Terminated | Trial primary completion date: Jul 2013 --> Jan 2014; Because of a very slow patient recruitment. Trial primary completion date: Jun 2014 --> Jun 2016
- | ianalumab (VAY736) / MorphoSys, Novartis
New P2 trial: PD of VAY736 in Patients With Primary Sjögren's Syndrome (clinicaltrials.gov) - Jun 27, 2014
P2, N=30, Recruiting, Sponsor: Novartis Pharmaceuticals
- | ianalumab (VAY736) / MorphoSys, Novartis
Enrollment open: PD of VAY736 in Patients With Primary Sjögren's Syndrome (clinicaltrials.gov) - Jun 27, 2014
P2, N=30, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2014 --> Jun 2016 Not yet recruiting --> Recruiting
- dexamethasone / Generic mfg.
Trial primary completion date: Dexamethasone Irrigation of the Parotid Glands in Primary Sj (clinicaltrials.gov) - Jun 19, 2014
P2, N=20, Recruiting, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2014 --> Jun 2015
- Trial completion: Evaluation of Therapeutic Effect of Bandage Contact Lenses ( BCL) on Dry Eye Caused by Sjogren's Syndrome (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=64, Completed, Sponsor: Jinyang Li
Trial primary completion date: Jun 2014 --> Jun 2015 Enrolling by invitation --> Completed
- | Trial completion: A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome (clinicaltrials.gov) - Jun 12, 2014
P4, N=42, Completed, Sponsor: Ocusoft, Inc.
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- |||| Orencia (abatacept) / BMS
Trial primary completion date: ASAPIII: Efficacy and Safety of Abatacept in Patients With Primary Sj (clinicaltrials.gov) - Jun 12, 2014
P3, N=88, Not yet recruiting, Sponsor: University Medical Centre Groningen
Active, not recruiting --> Completed Trial primary completion date: Jan 2017 --> Feb 2018
- hydrocortisone / Generic mfg.
Enrollment open: Endoscopic Treatment of Salivary Glands Affected by Sj (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=60, Recruiting, Sponsor: Derk Jan Jager
Trial primary completion date: Jan 2017 --> Feb 2018 Not yet recruiting --> Recruiting
- || New P3 trial: Treating Dry Eyes and Corneal Ulcers With Fingerprick Autologous Blood (clinicaltrials.gov) - Jun 1, 2014
P3, N=60, Enrolling by invitation, Sponsor: Bedford Hospital NHS Trust
- Trial initiation date: Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) - May 22, 2014
P=N/A, N=30, Recruiting, Sponsor: University of Rochester
Not yet recruiting --> Recruiting Initiation date: Feb 2014 --> Mar 2014
- Enrollment open: Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) - May 22, 2014
P=N/A, N=30, Recruiting, Sponsor: University of Rochester
Initiation date: Feb 2014 --> Mar 2014 Not yet recruiting --> Recruiting
- ||| R 348 / Rigel
Enrollment closed: To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca (clinicaltrials.gov) - May 21, 2014
P2, N=210, Active, not recruiting, Sponsor: Rigel Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Enrollment closed: A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES) (clinicaltrials.gov) - May 19, 2014
P2, N=90, Active, not recruiting, Sponsor: Mitotech, SA
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Biomarker, Enrollment open: Salivary Biomarkers for Sj (clinicaltrials.gov) - May 18, 2014
P=N/A, N=420, Recruiting, Sponsor: University of California, Los Angeles
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Vismed (sodium hyaluronate) / TRB Chemedica
Enrollment open: A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye (clinicaltrials.gov) - May 15, 2014
P4, N=80, Recruiting, Sponsor: Allergan
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | New P4 trial: A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome (clinicaltrials.gov) - May 13, 2014
P4, N=42, Active, not recruiting, Sponsor: Ocusoft, Inc.
- cyclosporin A microemulsion / Generic mfg.
Trial primary completion date: CYPRESS: Low Dose Cyclosporin A in Primary Sjögren Syndrome (clinicaltrials.gov) - May 6, 2014
P2, N=30, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2014 --> Oct 2014
- cyclosporin A microemulsion / Generic mfg.
Trial completion date: CYPRESS: Low Dose Cyclosporin A in Primary Sjögren Syndrome (clinicaltrials.gov) - May 6, 2014
P2, N=30, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Jan 2014 --> Oct 2014 Trial completion date: Mar 2014 --> Oct 2014
- cyclosporin A microemulsion / Generic mfg.
Enrollment closed: CYPRESS: Low Dose Cyclosporin A in Primary Sjögren Syndrome (clinicaltrials.gov) - May 6, 2014
P2, N=30, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Trial completion date: Mar 2014 --> Oct 2014 Recruiting --> Active, not recruiting
- Clinical: SPEEDCARS: Cross-sectional Study of Use of Speckle Method in Early Diagnosis of Cardiovascular Dysfunction (clinicaltrials.gov) - May 5, 2014
P=N/A, N=700, Active, not recruiting, Sponsor: University of Roma La Sapienza
- ||||| New P2 trial: A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES) (clinicaltrials.gov) - Apr 21, 2014
P2, N=90, Recruiting, Sponsor: Mitotech, SA
- |||| Enrollment open: A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES) (clinicaltrials.gov) - Apr 21, 2014
P2, N=90, Recruiting, Sponsor: Mitotech, SA
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Vismed (sodium hyaluronate) / TRB Chemedica
New P4 trial: A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye (clinicaltrials.gov) - Apr 17, 2014
P4, N=80, Not yet recruiting, Sponsor: Allergan
- Clinical: Examining the Immunological Process of Autoimmune Patients (clinicaltrials.gov) - Apr 15, 2014
P=N/A, N=200, Not yet recruiting, Sponsor: University of Florida
- hydrocortisone / Generic mfg.
Clinical: Endoscopic Treatment of Salivary Glands Affected by Sjögren's Syndrome (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=60, Not yet recruiting, Sponsor: Derk Jan Jager
- | New P2 trial: Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sj (clinicaltrials.gov) - Apr 8, 2014
P2, N=60, Active, not recruiting, Sponsor: Chang Gung Memorial Hospital
- | piclidenoson (CF101) - Can / Fite, Cipher, China Medical System
Trial completion: Trial of CF101 to Treat Patients With Dry Eye Disease (clinicaltrials.gov) - Mar 25, 2014
P3, N=237, Completed, Sponsor: Can-Fite BioPharma
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial initiation date: ETAP: Efficacy of Tocilizumab in Primary Sj (clinicaltrials.gov) - Mar 10, 2014
P2/3, N=110, Recruiting, Sponsor: University Hospital, Strasbourg, France
Recruiting --> Completed Initiation date: Mar 2013 --> Jul 2013